Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer

Clinical Cancer Research

Volumn 20, Issue 20, 2014, Pages 5281-5289

  Yu, Kenneth H ^a,b   Ricigliano, Mark ^c   Hidalgo, Manuel ^d   Abou Alfa, Ghassan K ^a,b   Lowery, Maeve A ^a,b   Saltz, Leonard B ^a,b   Crotty, Joseph F ^a,b   Gary, Kristen ^a,b   Cooper, Brandon ^e   Lapidus, Rena ^e   Sadowska, Mariola ^e   O'Reilly, Eileen M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CellPath Therapeutics   (United States)

^d Structural Biology and Biocomputing Programme   (Spain)

^e UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CD45 ANTIGEN; CYTOKERATIN; DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ABCC3 GENE; ADVANCED CANCER; AGED; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL ISOLATION; CIRCULATING TUMOR AND INVASIVE CELL; CIRCULATING TUMOR CELL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP2S1 GENE; CYP3A5 GENE; CYP51A1 GENE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSPORT; FEMALE; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHARMACOGENOMICS; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RELIABILITY; RNA EXTRACTION; SLC16A3 GENE; SLC17A5 GENE; SLC1A1 GENE; SLC20A1 GENE; SLC25A13 GENE; SLC25A3 GENE; SLC25A39 GENE; SLC25A5 GENE; SLC25A6 GENE; SLC2A10 GENE; SLC35B1 GENE; SLC39A14 GENE; SLC40A1 GENE; SLC44A1 GENE; SLC45A3 GENE; SLC6A8 GENE; SLC7A1 GENE; SLC9A3R1 GENE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; ADENOCARCINOMA; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHARMACOGENETICS; REPRODUCIBILITY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR EMBOLISM; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84909606439     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0531     Document Type: Article

References (21)

1. Matrisian LM, Aizenberg R, Rosenzweig A. The Alarming Rise of Pancreatic Cancer Deaths in the United States: Why We Need to Stem the Tide Today. Available from: http://www.pancan.org/section-research/reports/pdf/incidence-report-2012.pdf. Pancreatic Cancer Action Network; 2012.
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
3. Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). San Francisco, CA: ASCO 2013 Gastrointestinal Cancers Symposium; 2013.
4. Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 2013;31:4453-61.
5. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
6. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006;10:331-42.
7. Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ, et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 2010;126:669-83.
8. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett 2009;277:164-73.
9. Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML. Clinical signifi cance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 2009;112:185-91.
10. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
11. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 2009;8:713-24.
12. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007;104:13086-91.
13. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2010;16:711-8.
14. Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003;2:685-98.
15. DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug ef ficacy and toxicity. Annu Rev Pharmacol Toxicol 2012;52:249-73.
16. Januchowski R, Zawierucha P, Andrzejewska M, Rucinski M, Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother 2013;67:240-5.
17. McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004;3:363-71.
18. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 2012;9:454-67.
19. Yoshikawa K, Mitsunaga S, Kinoshita T, Konishi M, Takahashi S, Gotohda N, et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci 2012;103:2012-20.
20. Baine MJ, Chakraborty S, Smith LM, Mallya K, Sasson AR, Brand RE, et al. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS ONE 2011;6:e17014.
21. Angst E, Reber HA, Hines OJ, Eibl G. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 2008;144:57-65.